A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (COAST-X)

I1F-MC-RHBX -

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naive participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Axial Spondyloarthritis
What the trial is testing?
Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
303
Trial Dates
Aug 2, 2016 - May 7, 2019
How long will I be in the trial?
Your participation could last up to 1 ½ years and include 15 visits to the study center. After this study, you may be eligible to enter another study that could last up to 2 more years.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.